Optimisation of arterial hypertension pharmacotherapy in patients with metabolic syndrome: potential of zofenopril

被引:0
|
作者
Morozova, T. E. [1 ]
Andrushchishina, T. B. [1 ]
Oshorova, S. D. [1 ]
机构
[1] IM Sechenov First Moscow State Med Univ, Minist Hlth Care and Social Dev Russia, Moscow, Russia
来源
RUSSIAN JOURNAL OF CARDIOLOGY | 2011年 / 04期
关键词
Arterial hypertension; metabolic syndrome; zofenopril; pleiotropic effects; MYOCARDIAL-INFARCTION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic syndrome (MS) is an important problem of the modern medicine, due to its substantial impact on cardiovascular risk. Visceral fat tissue is an endocrine organ, producing a wide spectrum of biologically active substances - adipokines, which influence atherosclerosis progression, thrombosis, insulin resistance, and other processes. The aim of this study was to assess the activity of adipokines, endothelial dysfunction markers, and systemic inflammation, in patients with arterial hypertension (AN) and MS, who received an ACE inhibitor zofenopril. This open study of pleiotropic and antihypertensive effects of zofenopril included 32 patients with Stage I-II All and MS (18 men, 14 women; mean age 54 years (from 48 to 60,5 years)). Zofenopril demonstrated not only a good antihypertensive effect, but also a significant (p=0,001) decrease in leptin levels, from 18,7 ng/ml (12,8;34,0) to 17,5 ng/ml (12,5;30,6); some increase (p=0,12) in adiponectin levels, from 10,4 mkg/ml (7,5;14,1) to 13,6 mkg/ml (6,5;17,7); a significant (p=0,001) reduction in endothelin-1 activity, from 0,38 fmol/l (0,25;1,03) to 0,34 fmol/l (0,14;0,88); and a slight decrease (p=0,03) in intercellular adhesion molecule ([CAM) levels, from 323,9 ng/ml (242,25;512,31) to 315,47 ng/ml (187,31;424,38).
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [1] COMBINED PHARMACOTHERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION ASSOCIATED WITH METABOLIC SYNDROME
    Abasova, L., I
    Dashdamirov, R. L.
    Bahshaliev, A. B.
    WORLD OF MEDICINE AND BIOLOGY, 2011, 28 (01): : 53 - 55
  • [2] Effects of Zofenopril on Arterial Stiffness in Hypertension Patients
    Palic, Benjamin
    Brizic, Ivica
    Sher, Emina Karahmet
    Cvetkovic, Ivona
    Dzidic-Krivic, Amina
    Abdelghani, Heba Taha Mohmmed
    Sher, Farooq
    MOLECULAR BIOTECHNOLOGY, 2023,
  • [3] Uricemia and metabolic syndrome in patients with arterial hypertension
    Pascual Izuel, J. M.
    REVISTA CLINICA ESPANOLA, 2012, 212 (09): : 440 - 441
  • [4] METABOLIC SYNDROME - SIGNIFICANCE FOR PHARMACOTHERAPY OF HYPERTENSION
    SCHREY, A
    HERZ KREISLAUF, 1994, 26 (09): : R3 - +
  • [5] Analysis of arterial hypertension pharmacotherapy in patients with obstructive sleep apnea syndrome
    Sova, Milan
    Sovova, Eliska
    Hobzova, Milada
    Urbanek, Karel
    Zapletalova, Jana
    Kamasova, Monika
    Barinova, Denisa
    Gottfriedova, Barbora
    Kuca, Irena
    Kolek, Vitezslav
    COR ET VASA, 2015, 57 (03) : E157 - E162
  • [6] Pharmacotherapy of arterial hypertension in patients with psoriasis
    Dodulik, Jozef
    Dodulikova, Lenka
    Plasek, Jiri
    Ramik, Zdenek
    Vrtal, Jiri
    Vaclavik, Jan
    JOURNAL OF HYPERTENSION, 2025, 43 (04) : 568 - 576
  • [7] Insulin Resistance in Patients with Arterial Hypertension and Metabolic Syndrome
    Shlyakhto, Evgeny
    Chubenko, Ekaterina
    Belyaeva, Olga
    Berkovich, Olga
    Karonova, Tatiana
    Baranova, Elena
    HYPERTENSION, 2011, 58 (05) : E115 - E116
  • [8] Heart pathology in patients with arterial hypertension and metabolic syndrome
    Sharipova, G. Kh.
    Ataullakhanova, D. M.
    Mychka, V. B.
    Saidova, M. A.
    Chazova, I. E. A. L.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2008, 7 (08): : 20 - 26
  • [9] PECULIARITIES OF TREATMENT OF ARTERIAL HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME
    Gaspar, Ludovit
    Mesarosova, Dasa
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL 1) : E270 - E270
  • [10] Acarbose in patients with mild arterial hypertension and metabolic syndrome
    Bogieva, R
    Mychka, V
    Masenko, V
    Chazova, I
    JOURNAL OF HYPERTENSION, 2004, 22 : S91 - S92